Objectives: Among considerable efforts to improve quality of surgical care, expedited measures such as a selective referral to high-volume institutions have been advocated. Our objective was to examine whether racial, insurance and/or socioeconomic disparities exist in the use of high-volume hospitals for complex surgical oncological procedures within the USA.
Design, Setting And Participants: Patients undergoing colectomy, cystectomy, oesophagectomy, gastrectomy, hysterectomy, lung resection, pancreatectomy or prostatectomy were identified retrospectively, using the Nationwide Inpatient Sample, between years 1999 and 2009. This resulted in a weighted estimate of 2 508 916 patients.
Primary Outcome Measures: Distribution of patients according to race, insurance and income characteristics was examined according to low-volume and high-volume hospitals (highest 20% of patients according to the procedure-specific mean annual volume). Generalised linear regression models for prediction of access to high-volume hospitals were performed.
Results: Insurance providers and county income levels varied differently according to patients' race. Most Caucasians resided in wealthier counties, regardless of insurance types (private/Medicare), while most African Americans resided in less wealthy counties (≤$24 999), despite being privately insured. In general, Caucasians, privately insured, and those residing in wealthier counties (≥$45 000) were more likely to receive surgery at high-volume hospitals, even after adjustment for all other patient-specific characteristics. Depending on the procedure, some disparities were more prominent, but the overall trend suggests a collinear effect for race, insurance type and county income levels.
Conclusions: Prevailing disparities exist according to several patient and sociodemographic characteristics for utilisation of high-volume hospitals. Efforts should be made to directly reduce such disparities and ensure equal healthcare delivery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963094 | PMC |
http://dx.doi.org/10.1136/bmjopen-2013-003921 | DOI Listing |
Global Spine J
January 2025
Department of Spinal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Study Design: Retrospective Cohort Study.
Objectives: The current recommended treatment for Giant Cell Tumour (GCT) of the spine is en bloc excision. Denosumab is a monoclonal antibody reducing osteoclast activity that shows promising results when used as a neo - adjuvant treatment.
Alzheimers Dement
December 2024
University of Geneva, Geneva, Switzerland
Background: Plasma biomarkers have been increasingly studied in Alzheimer’s disease due to their potentially high accessibility, affordability, and low invasiveness. Recent studies have shown that baseline plasma levels are capable of predicting cognitive decline in cognitively unimpaired subjects (CU) and with mild cognitive impairment (MCI). Despite the fact that neuroimaging biomarkers are also strong predictors, it is still unclear how well they perform when compared to plasma biomarkers in predicting cognitive deterioration.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Radiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland
Background: Hippocampal atrophy is an established biomarker of neurodegeneration in Alzheimer's disease, affecting specific subfields (De Flores, La Joie and Chételat, 2015). In this study, we used 7T MRI and advanced diffusion MRI (dMRI) to investigate the relationship between hippocampal subfield volumes and microstructure and assess their sensitivity to cognitive impairment.
Method: Seventeen cognitively impaired (CI; age: 69±8, M/F: 12/5, MMSE: 28) and 22 cognitively unimpaired subjects (CU; age: 62±10, M/F: 6/16) were recruited in the context of the COSCODE project (Ribaldi et al.
Alzheimers Dement
December 2024
Africa Mental Health Research and Training Foundation, Nairobi, Kenya
Background: Plasma/serum measurements, which stand as the clinical gold standard biomarkers for Alzheimer’s disease (AD) are minimally invasive, facilitating easy collection and processing particularly in low‐resource settings. Often, both laboratory and non‐laboratory medical personnel find themselves collecting these blood biomarker samples in remote hospitals characterized by a high influx of patients, leaving them with limited time and resources (e.g.
View Article and Find Full Text PDFCrit Care Resusc
December 2024
Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
Objective: Extracorporeal membrane oxygenation (ECMO) is a high-risk procedure with significant morbidity and mortality and there is an uncertain volume-outcome relationship, especially regarding long-term functional outcomes. The aim of this study was to examine the association between ECMO centre volume and long-term death and disability outcomes.
Design Setting And Participants: This is a registry-embedded observational cohort study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!